Join the Zepbound group to help and get support from people like you.
Zepbound News (Page 4)
GLP-1 Receptor Agonist Zepbound Approved as First Drug for Obstructive Sleep Apnea in Individuals with Obesity
MONDAY, Dec. 23, 2024 – The U.S. Food and Drug Administration (FDA) has approved the first prescription medication specifically for treating obstructive sleep apnea (OSA): the weight-loss drug...
FDA Says Shortage of GLP-1 Tirzepatide (Mounjaro, Zepbound) Is Over
THURSDAY, Dec. 19, 2024 – The U.S. Food and Drug Administration re-issued a decision first made by the agency in October that a shortage of the diabetes/weight-loss medication tirzepatide is over....
U.S. Adult Obesity Rate Fell in 2023, as Use of GLP-1 Meds Rose
FRIDAY, Dec. 13, 2024 – The U.S. obesity rate declined for the first time in a decade last year, coinciding with the rise of GLP-1 weight-loss meds, a new study finds. Data on almost 17 million...
Weight Loss Brings Americans Big Health Care Savings
THURSDAY, Dec. 5, 2024 – The advent of GLP-1 weight-loss medications such as Wegovy and Zepbound has spurred debate as to whether the drugs' cost should be covered by Medicare, Medicaid and private...
Zepbound Bests Wegovy for Weight Loss in New Trial
WEDNESDAY, Dec. 4, 2024 – Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical trial funded by Lilly. "Given the increased...
American Heart Association, Nov. 16-18
The annual meeting of the American Heart Association was held this year from Nov. 16 to 18 in Chicago, drawing attendees from around the world, including cardiovascular specialists, surgeons, and n...
Biden Seeks Coverage for GLP-1 RA Medications by Medicare, Medicaid
TUESDAY, Nov. 26, 2024 – The Biden administration is proposing Medicare and Medicaid coverage for glucagon-like peptide 1 receptor agonist (GLP-1 RA) obesity medications like semaglutide (Wegovy)...
Zepbound Slashes Diabetes Risk in Obese Users
WEDNESDAY, Nov. 27, 2024 – The cutting-edge weight-loss drug Zepbound can protect obese people from developing type 2 diabetes, a new clinical trial has found. Zepbound reduced the risk of diabetes...
Biden Will Move to Have Medicare, Medicaid Cover GLP-1 Weight-Loss Meds, such as Wegovy, Zepbound
TUESDAY, Nov. 26, 2024 – The outgoing Biden administration will propose that pricey GLP-1 obesity medications such as semaglutide (Wegovy), and tirzepatide (Zepbound) be covered by Medicare and...
Taking a GLP-1 Medication? Here's Tips to Holiday Eating
SATURDAY, Nov. 23, 2024 – So, you have managed to shed 30 pounds with the help of one of the new blockbuster GLP-1 drugs, but as the holidays near you worry about how to handle gatherings where...
Meds Like Ozempic Are Causing Folks to Waste More Food
FRIDAY, Nov. 22, 2024 – America's kitchen trash bins are receiving more unwanted food as appetites falter among people taking GLP-1 weight-loss meds, a new study shows. GLP-1s like Ozempic, Wegovy,...
AHA: Tirzepatide Beneficial for Heart Failure With Preserved EF, Obesity
FRIDAY, Nov. 22, 2024 – For patients with heart failure with preserved ejection fraction, tirzepatide yields a reduced risk for a composite of death from cardiovascular causes or worsening heart...
Weight-Loss Drug Zepbound May Lower Heart Failure Deaths
THURSDAY, Nov. 21, 2024 – A drug used to help patients lose weight and manage diabetes may also help those with heart failure, an international clinical trial shows. The test of tirzepatide, brand...
Tirzepatide Yields Sustained Weight Reduction in Obesity, Prediabetes
MONDAY, Nov. 18, 2024 – For patients with obesity and prediabetes, three years of tirzepatide yields substantial and sustained weight reduction and a reduced risk for progression to type 2 diabetes,...
AHA: GLP-1 RA, SGLT-2i Use Can Lower Risk for MI, Recurrent Stroke in Stroke Survivors
TUESDAY, Nov. 12, 2024 – For patients with ischemic stroke, sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with reduced...
Further information
Related condition support groups
Weight Loss (Obesity / Overweight), Obstructive Sleep Apnea/Hypopnea Syndrome